UCLA study finds drug could have ability to reduce lung cancer cell growth “In a recent study, researchers at UCLA found a drug that can limit the growth of certain lung cancer cells.” FDA Accelerated Approval of Adagrasib for Non-Small Cell Lung Cancer “Kirsten rat sarcoma viral oncogene homologue (KRAS) mutations occur in approximately 30 percent of non-small cell lung cancers (NSCLCs) and KRASG12C is the most common mutation in KRAS-mutant NSCLC. Despite advances in the treatment of NSCLC, there are limited treatment options for patients with this debilitating and difficult-to-treat condition. Thus, KRASG12C-mutated NSCLC is an area of critical unmet need.” The Evolution of PD-L1 from Pre-invasive to Invasive Lung Cancer “The purpose of this study was to examine the possible association of the PD-L1 pathway with the early evolution of lung adenocarcinoma by evaluating the expression of programmed cell death-ligand 1 (PD-L1) from pre-invasive to invasive adenocarcinoma. Researchers analyzed PD-L1 expression in 1,123 lung tissue samples from patients with stage IA1-IA3 adenocarcinoma in situ (AIS), minimally invasive adenocarcinoma (MIA), and invasive adenocarcinoma (IAC). The tumor proportion score was used to categorize PD-L1 expression as < 1% (negative),  ≥ 1%, positive (1%), or ≥ (50%) (strongly positive).” Treatment for Relapsed SCLC Remains “Area of High Unmet Need” “There is a lack of promising investigational treatments in late-stage development for small-cell lung cancer (SCLC) in the second-line setting and beyond, according to a systematic review published in Clinical Lung Cancer.” Lucence Liquid Biopsy Test to Receive Medicare Reimbursement in Lung Cancer NEW YORK – “Lucence said Wednesday that its LiquidHallmark liquid biopsy test is now covered under a local coverage decision from Medicare administrative contractor Palmetto GBA, through its MolDx technology assessment group.” Video: Why Patients with Lung Cancer Should Broaden Their Horizon “As a part of its Speaking Out Video series, CURE® spoke with Terri Conneran, on behalf of KRAS Kickers, about networking during a lung cancer diagnosis.” Dr. Chao on the Study of PD-L1 Inhibitors with NSCLC “Yvonne Chao, MD, PhD, member, Cancer Biology Program, UPMC Hillman Cancer Center, assistant professor, Division of Hematology/Oncology, University of Pittsburgh School of Medicine, discusses the study of various PD-L1 inhibitors in patients with non–small cell lung cancer (NSCLC).”